中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 9
Sep.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(9): 2061-2066

Prognostic value of several immune and inflammatory indices after curative-intent resection for intrahepatic cholangiocarcinoma

DOI: 10.3969/j.issn.1001-5256.2022.09.021
  • 1a.

    Department of Hepatopancreatobiliary Surgery, Affiliated Hospital of Weifang Medical University, Weifang, Shandong 261031, China

  • 1b.

    Department of Dermatology, Affiliated Hospital of Weifang Medical University, Weifang, Shandong 261031, China

  • 2.

    Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China

  • 3.

    Department of Hepatobiliary, Pancreatic and Splenic Surgery, The People's Hospital of Guangxi Zhuang Autonomous Region & Guangxi Academy of Medical Sciences, Nanning 530021, China

Research funding:

Medical and Health Science and Technology Development Plan of Shandong Province (202004011537);

Weifang Science and Technology Development Program(Medical Science) (2020YX085);

Medical Research and Development Fund—Clinical and Basic Research Project (TB205004)

More Information
  • Corresponding author: LI Shiping, lishipingwyfy@126.com(ORCID: 0000-0001-9144-0180)
  • Received Date: 2022-03-06
  • Accepted Date: 2022-04-18
  • Published Date: 2022-09-20
    Abstract
  •   Objective  To investigate the value of different immune and inflammatory indices in predicting the survival outcome of patients with intrahepatic cholangiocarcinoma (ICC) after curative-intent resection.  Methods  A retrospective analysis was performed for the case data of 122 patients with ICC who underwent curative-intent resection in Affiliated Hospital of Weifang Medical University and Tianjin Medical University Cancer Institute and Hospital from January 2012 to December 2017 to analyze the correlation of neutrophil-lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR), systemic immune-inflammation index (SII), prognostic inflammation index (PII), inflammation score (IS), and systemic inflammation score (SIS) with the disease-free survival (DFS) and overall survival of ICC patients after surgery, and the value of the above indices in predicting prognosis was evaluated. The chi-square test or the Fisher's exact test was used for comparison of categorical data between groups. The Kaplan-Meier method was used to plot survival curves, and the Log-rank test was used for comparison between groups; the Cox regression model was used for univariate and multivariate analyses, and hazard ratio (HR) and 95% confidence interval [CI] were calculated.  Results  The univariate survival analysis showed that NLR (HR=2.212, P=0.004), LMR (HR=0.403, P=0.012), PII (HR=3.013, P < 0.001), prognostic nutritional index (PNI) (HR=0.530, P=0.019), IS (HR=1.809, P=0.001), SII (HR=2.107, P=0.002), and SIS (HR=2.225, P < 0.001) were predictive factors for postoperative DFS of patients with ICC, and NLR (HR=2.416, P=0.009), LMR (HR=0.297, P=0.008), PII (HR=3.288, P < 0.001), PNI (HR=0.292, P=0.003), IS (HR=2.048, P=0.002), SII (HR=1.839, P=0.049), and SIS (HR=2.335, P < 0.001) were predictive factors for postoperative OS of patients with ICC. The multivariate survival analysis showed that high levels of PII (HR=2.146, P=0.035) and SIS (HR=2.511, P < 0.001) were independent influencing factors for postoperative DFS of ICC patients, and high levels of PII (HR=2.981, P=0.009), PNI (HR=0.261, P=0.002), and SIS (HR=2.294, P=0.010) were independent influencing factors for postoperative OS. The patients with a high level of PII tended to have advanced tumor T stage (χ2=8.777, P=0.003) and M stage (P=0.029), and the patients with high-grade SIS tended to have advanced N stage (χ2=9.985, P=0.030) and M stage (χ2=8.574, P=0.012).  Conclusion  Among the various inflammation indices, PII and SIS are recommended for preoperative stratification and prediction of the outcome of ICC patients after curative-intent resection.

     

    • FullText(HTML)
  • loading
    • References(15)
  • [1]
    BERGQUIST A, von SETH E. Epidemiology of cholangiocarcinoma[J]. Best Pract Res Clin Gastroenterol, 2015, 29(2): 221-232. DOI: 10.1016/j.bpg.2015.02.003.
    [2]
    TAN JC, COBURN NG, BAXTER NN, et al. Surgical management of intrahepatic cholangiocarcinoma-a population-based study[J]. Ann Surg Oncol, 2008, 15(2): 600-608. DOI: 10.1245/s10434-007-9627-x.
    [3]
    SI A, LI J, YANG Z, et al. Impact of anatomical versus non-anatomical liver resection on short- and long-term outcomes for patients with intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol, 2019, 26(6): 1841-1850. DOI: 10.1245/s10434-019-07260-8.
    [4]
    WANG DS, LUO HY, QIU MZ, et al. Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer[J]. Med Oncol, 2012, 29(5): 3092-3100. DOI: 10.1007/s12032-012-0226-8.
    [5]
    KINOSHITA A, ONODA H, IMAI N, et al. Comparison of the prognostic value of inflammation-based prognostic scores in patients with hepatocellular carcinoma[J]. Br J Cancer, 2012, 107(6): 988-993. DOI: 10.1038/bjc.2012.354.
    [6]
    LIN J, FANG T, ZHU M, et al. Comparative performance of inflammation-based prognostic scores in patients operated for intrahepatic cholangiocarcinoma[J]. Cancer Manag Res, 2019, 11: 9107-9119. DOI: 10.2147/CMAR.S198959.
    [7]
    CHEN Q, DAI Z, YIN D, et al. Negative impact of preoperative platelet-lymphocyte ratio on outcome after hepatic resection for intrahepatic cholangiocarcinoma[J]. Medicine (Baltimore), 2015, 94(13): e574. DOI: 10.1097/MD.0000000000000574.
    [8]
    OHIRA M, YOSHIZUMI T, YUGAWA K, et al. Association of inflammatory biomarkers with long-term outcomes after curative surgery for mass-forming intrahepatic cholangiocarcinoma[J]. Surg Today, 2020, 50(4): 379-388. DOI: 10.1007/s00595-019-01905-7.
    [9]
    MA B, MENG H, SHEN A, et al. Prognostic value of inflammatory and tumour markers in small-duct subtype intrahepatic cholangiocarcinoma after curative-intent resection[J]. Gastroenterol Res Pract, 2021, 2021: 6616062. DOI: 10.1155/2021/6616062.
    [10]
    ZHANG Y, SHI SM, YANG H, et al. Systemic inflammation score predicts survival in patients with intrahepatic cholangiocarcinoma undergoing curative resection[J]. J Cancer, 2019, 10(2): 494-503. DOI: 10.7150/jca.26890.
    [11]
    SELLERS CM, UHLIG J, LUDWIG JM, et al. Inflammatory markers in intrahepatic cholangiocarcinoma: Effects of advanced liver disease[J]. Cancer Med, 2019, 8(13): 5916-5929. DOI: 10.1002/cam4.2373.
    [12]
    CANNA K, MCARDLE PA, MCMILLAN DC, et al. The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer[J]. Br J Cancer, 2005, 92(4): 651-654. DOI: 10.1038/sj.bjc.6602419.
    [13]
    MA B, MENG H, TIAN Y, et al. High expression of HVEM is associated with improved prognosis in intrahepatic cholangiocarcinoma[J]. Oncol Lett, 2021, 21(1): 69. DOI: 10.3892/ol.2020.12330.
    [14]
    ZHOU SL, DAI Z, ZHOU ZJ, et al. CXCL5 contributes to tumor metastasis and recurrence of intrahepatic cholangiocarcinoma by recruiting infiltrative intratumoral neutrophils[J]. Carcinogenesis, 2014, 35(3): 597-605. DOI: 10.1093/carcin/bgt397.
    [15]
    MA B, MENG H, TIAN Y, et al. Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma[J]. BMC Cancer, 2020, 20(1): 318. DOI: 10.1186/s12885-020-06804-6.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (444) PDF downloads(57) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return